Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ProQR Therapeutics N.V. PRQR NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • NL • USD

SharesGrow Score
57/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$3.63
+82.4%

ProQR Therapeutics N.V. (PRQR) is a Biotechnology company in the Healthcare sector, currently trading at $1.99. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is PRQR = $4 (+82.4% upside).

Valuation: PRQR trades at a trailing Price-to-Earnings (P/E) of -4.2 (S&P 500 average ~25).

Financials: revenue is $15M, +77.5%/yr average growth. Net income is $41M (loss), growing at +4%/yr. Net profit margin is -265.2% (negative). Gross margin is 83% (+44.3 pp trend).

Balance sheet: total debt is $14M against $49M equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 3.09 (strong liquidity). Debt-to-assets is 12.4%. Total assets: $113M.

Analyst outlook: 9 / 10 analysts rate PRQR as buy (90%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 73/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$3.63
▲ 82.41% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for ProQR Therapeutics N.V., the average price target is $3.63, with a high forecast of $5.00, and a low forecast of $2.00.
Highest Price Target
$5.00
Average Price Target
$3.63
Lowest Price Target
$2.00

PRQR SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PRQR

✓
VALUE Pass
100/100
PRQR trades at a trailing Price-to-Earnings (P/E) of -4.2 (S&P 500 average ~25). Forward PEG -0.22 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $4, implying +101% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
73/100
PRQR: +77.5%/yr revenue is, +4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PRQR: Debt-to-Equity (D/E) ratio 0.28 (conservative), Current ratio is 3.09 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
PRQR: Gross margin is 83% (+44.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 9 / 10 analysts rate PRQR as buy (90%). Analyst consensus target is $4 (+101% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
PRQR: Net profit margin is -265.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.07-3.1
Volume456.49K
Avg Volume (30D)441.16K
Market Cap$209.67M
Beta (1Y)0.09
Share Statistics
EPS (TTM)-0.38
Shares Outstanding$105.33M
IPO Date2014-09-18
Employees166
CEODaniel Anton de Boer
Financial Highlights & Ratios
Revenue (TTM)$15.28M
Gross Profit$12.68M
EBITDA$-39.56M
Net Income$-40.52M
Operating Income$-42.15M
Total Cash$92.37M
Total Debt$13.99M
Net Debt$-78.39M
Total Assets$112.71M
Price / Earnings (P/E)-5.2
Price / Sales (P/S)13.72
Analyst Forecast
1Y Price Target$3.75
Target High$5.00
Target Low$2.00
Upside+88.4%
Rating ConsensusBuy
Analysts Covering10
Buy 90% Hold 10% Sell 0%
Price Target Summary
Company Info
CountryNL
ExchangeNASDAQ Global Market
CurrencyUSD
ISINNL0010872495

Price Chart

Track all markets on TradingView
PRQR
ProQR Therapeutics N.V. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.07 52WK RANGE 3.10

People Also View

ALNY
ALNY
Alnylam Pharmaceuticals, Inc.
$339.41
+1.92%
 ARWR
ARWR
Arrowhead Pharmaceuticals, Inc.
$66.69
+4.55%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 WVE
WVE
Wave Life Sciences Ltd.
$7.39
+1.79%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message